Cell line · CVCL_3936
Papers32
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinical and Functional Characterization of PDE1A as a Wnt/β-Catenin-Linked Biomarker of Progression and Platinum Resistance in Epithelial Ovarian Cancer. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EMSY enhances glycolysis in ovarian cancer cells. | Eur J Med Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39282307 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Claudin-4 Modulates Autophagy via SLC1A5/LAT1 as a Mechanism to Regulate Micronuclei. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. | Cancer Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. | Cell Rep | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. | Genome Med | 2015 | Cellosaurus cites it | PubMed | |
| A resource for cell line authentication, annotation and quality control. | Nature | 2015 | Cellosaurus cites it | PubMed | |
| A comprehensive transcriptional portrait of human cancer cell lines. | Nat Biotechnol | 2015 | Cellosaurus cites it | PubMed | |
| DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. | Gynecol Oncol | 2012 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3936/papers